Recent publications on Crucell’s core technologies and vaccine/antibody/ protein development programs are listed below. The articles have been grouped according to the technologies used. Please click on any of these to access the abstracts of the articles.

For more Crucell scientific papers please use search word ‘Crucell’ at the website of PubMed.

• Havenga, M.; Vogels, R.; Zuijdgeest, D.; Radosevic, K.; Mueller, S.; Sieuwerts, M.; Weichold, F.; Damen, I.; Kaspers, J.; Lemckert, A.; Meerendonk, M.van; Vlugt, R. Van Der; Holterman, L.; Hone, D.; Skeiky, Y.; Mintardjo, R.; Gillissen, G.; Barouch, D.; Sadoff, J.; Goudsmit, J. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol. 2006. 87(Pt 8), 2135-2143.

• Kapteyn, J.C.; Saidi, M.D.; Kijkstra, R.; Kars, C.; Tjon, J.C.; Weverling, G.J.; Vocht, M.L.D.; Kompier, R.; Montfort, B.A.V.; Guichoux, J.Y.; Goudsmit, J.; Lagerwerf, F.M. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine. 2006. 24(16), 3137-3144.
• Ledwith, B.J.; Lanning, C.L.; Gumprecht, L.A.; Anderson, C.A.; Coleman, J.B.; Gatto, N.T.; Balasubramanian, G.; Farris, G.M.; Kemp, R.K.; Harper, L.B.; Barnum, A.B.; Pacchione, S.J.; Mauer, K.L.; Troilo, P.F.; Brown, E.R.; Wolf, J.J.; Lebronl, J.A.; Lewis, J.A.; Nichols, W.W. Tumorigenicity assessments of Per.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line. Dev Biol (Basel). 2006. 123, 251-263; discussion 265-266.
• Lewis, J.A.; Brown, E.L.; Duncan, P.A. Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. Dev Biol (Basel). 2006. 123, 165-176; discussion 183-197.
• Maranga, L.; Aunins, J.G.; Zhou, W. Characterization of changes in PER.C6 trade mark cellular metabolism during growth and propagation of a replication-deficient adenovirus vector. Biotechnol Bioeng. 2005. 90(5), 645-655.
• Kwaks, T.H.; Sewalt, R.G.; Van Blokland, R.; Siersma, T.J.; Kasiem, M.; Kelder, A.; Otte, A.P. Targeting of a histone acetyltransferase domain to a promoter enhances protein expression levels in mammalian cells. J Biotechnol. 2005. 115(1), 35-46.
• Gijsbers, L.; Koel, B.; Weggeman, M.; Goudsmit, J.; Havenga, M.; Marzio, G. Quantification of residual host cell DNA in adenoviral vectors produced on PER.C6® cells. Hum Gene Ther. 2005. 16(3), 393-398.
• Murakami P.; Havenga M.; Fawaz F.; Vogels R.; Marzio G.; Pungor E.; Files J.; Do L.; Goudsmit J.; McCaman M. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. J Virol. 2004. 78(12), 6200-6208.
• Jones D.; Kroos N.; Anema R.; van Montfoort B.; Vooys A.; van der Kraats S.; van der Helm E.; Smits S.; Schouten J.; Brouwer K.; Lagerwerf F.; van Berkel P.; Opstelten D.J.; Logtenberg T.; Bout A. High Level expression of recombinant IgG in the human cell line PER.C6™. Biotechnol Prog. 2003. 19(1), 163-168.
• Kirschweger G. Crucell: biopharmaceuticals -- as human as they get. Mol Ther. 2003. 7(1), 5-6.
• Nichols W.; Lardenoije R.; Ledwith B.; Brower K.; Manam S.; Vogels R.; Kaslow D.; Zuidgeest D.; Bett A.; Chen L.; van der Kaaden M.; Galloway S.; Hill R.; Machotka S.; Anderson C.; Lewis J.; Martinez D.; Lebron J.; Russo C.; Valerio D.; Bout A. Propagation of Adenoviral Vectors: Use of PER.C6^® Cells. 2002. In "Adenoviral Vectors for Gene Therapy", pp. 129-166. Elsevier Science, USA.

• Ophorst, O.J.; Radosevic, K.; Havenga, M.J.; Pau, M.G.; Holterman, L.; Berkhout, B.; Goudsmit, J.; Tsuji, M. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun. 2006. 74, 313-320.
• Roberts, D.M.; Nanda, A.; Havenga, M.J.; Abbink, P.; Lynch, D.M.; Ewald, B.A.; Liu, J.; Thorner, A.R.; Swanson, P.E.; Gorgone, D.A.; Lifton, M.A.; Lemckert, A.A.; Holterman, L.; Chen, B.; Dilraj, A.; Carville, A.; Mansfield, K.G.; Goudsmit, J.; Barouch, D.H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006. 441, 239-243.
• Sumida, S.M., Truitt, D.M., Lemckert, A.A., Vogels, R., Custers, J.H., Addo, M.M., Lockman, S., Peter, T., Peyerl, F.W., Kishko, M.G., Jackson, S.S., Gorgone, D.A., Lifton, M.A., Essex, M., Walker, B.D., Goudsmit, J., Havenga, M.J., And Barouch, D.H. Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein. J Immunol. 2005. 174(11), 7179-7185
• Lusky, M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther. 2005. 16(3), 281-291.
• Heppner D.G. Jr; Kester K.E.; Ockenhouse C.F.; Tornieporth N; Ofori O; Lyon J.A.; Stewart V.A.; Dubois P.; Lanar D.E.; Krzych U.; Moris P.; Angov E.; Cummings J.F.; Leach A.; Hall B.T.; Dutta S.; Schwenk R.; Hillier C.; Barbosa A.; Ware L.A.; Nair L.; Darko C.A.; Withers M.R.; Ogutu B.; Polhemus M.E.; Fukuda M.; Pichyangkul S.; Gettyacamin M.; Diggs C.; Soisson L.; Milman J.; Dubois M.C.; Garcon N.; Tucker K.; Wittes J.; Plowe C.V.; Thera M.A.; Duombo O.K.; Pau M.G.; Goudsmit J.; Ballou W.R.; Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005. 23(17-18), 2243-2250.
• Goncalves, M.; Van Nierop, G.; Tijssen, M.; Lefesvre, P.; Knaan-Shanzer, S.; Van Der Velde, I.; Van Bekkum, D.; Valerio, D.; De Vries, A. Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. J Virol. 2005. 79(5), 3146-3162
• Eleveld-Trancikova, D.; Triantis, V.; Moulin, V.; Looman, M.; Wijers, M.; Fransen, J.; Lemckert, A.; Havenga, M.; Figdor, C.; Janssen, R.; Adema, G. The dendritic cell-derived protein DC-STAMP is highly conserved and localizes to the endoplasmic reticulum. J Leukoc Biol. 2005. 77(3), 337-34
• Holterman L.; Vogels R.; van der Vlugt R.; Sieuwerts M.; Grimbergen J.; Kaspers J.; Geelen E.; van der Helm E.; Lemckert A.; Gillissen G.; Verhaagh S.; Custers J.; Zuijdgeest D.; Berkhout B.; Bakker M.; Quax P.; Goudsmit J.; Havenga M. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol. 2004. 78(23), 13207-13215.
• Kostense S.; Koudstaal W.; Sprangers M.; Weverling G.J.; Penders G.; Helmus N.; Vogels R.; Bakker M.; Berkhout B.; Havenga M.; Goudsmit J. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004. 18(8), 1213-1216.
• Mercier S.; Verhaagh S.; Goudsmit J.; Lemckert A.; Monteil M.; Havenga M.; Eloit M. Adenovirus fibre exchange alters cell tropism in vitro but not transgene-specific T CD8+ immune responses in vivo. J Gen Virol. 2004. 85(Pt 5), 1227-1236.
• Ophorst O.J.; Kostense S.; Goudsmit J.; De Swart R.L.; Verhaagh S.; Zakhartchouk A.; Van Meijer M.; Sprangers M.; Van Amerongen G.; Yuksel S.; Osterhaus A.D.; Havenga M.J. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity. Vaccine. 2004. 22(23-24), 3035-3044.
• Slager E.H.; van der Minne C.E.; Goudsmit J.; van Oers J.M.; Kostense S.; Havenga M.J.; Osanto S.; Griffioen M. Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 2004. 11(3), 227-236.
• Sumida S.M.; Truitt D.M.; Kishko M.G.; Arthur J.C.; Jackson S.S.; Gorgone D.A.; Lifton M.A.; Koudstaal W.; Pau M.G.; Kostense S.; Havenga M.J.; Goudsmit J.; Letvin N.L.;, Barouch D.H. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol. 2004. 78(6), 2666-2673.
• Barouch D.H.; Pau M.G.; Custers J.H.; Koudstaal W.; Kostense S.; Havenga M.J.; Truitt D.M.; Sumida S.M.; Kishko M.G.; Arthur J.C.; Korioth-Schmitz B.; Newberg M.H.; Gorgone D.A.; Lifton M.A.; Panicali D.L.; Nabel G.J.; Letvin N.L.; Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-ad5 immunity. J Immun. 2004. 172(10), 6290-6297.
• Vogels R.; Zuijdgeest D.; van Rijsoever R.; Hartkoorn E.; Damen I.; de Bethune M.P.; Kostense S.; Penders G.; Helmus N.; Koudstaal W.; Cecchini M.; Wetterwald A.; Sprangers M.; Lemckert A.; Ophorst O.; Koel B.; van Meerendonk M.; Quax P.; Panitti L.; Grimbergen J.; Bout A.; Goudsmit J.; Havenga M. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003. 77(15), 8263-8271.
• Havenga M.; Lemckert A.; Ophorst O.; van Meijer M.; Germeraad W.; Grimbergen J.; van den Doel M.; Vogels R.; van Deutekom J.; Janson A.; de Bruijn J.; Uytdehaag F.; Quax P.; Logtenberg T.; Methali, M.; Bout A. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol. 2002. 76(9), 4612-4620.

• Kruif, J. de; Bakker, A.B.; Marissen, W.E.; Kramer, R.A.; Throsby, M.; Rupprecht, C.E.; Goudsmit, J. (2006). A Human Monoclonal Antibody Cocktail as a Novel Component of Rabies Postexposure Prophylaxis. Annual Rev Med. Review in advance. Published online August 3, 2006.
• ter Meulen J.; van den Brink E.N.; Poon L.L.; Marissen W.E.; Leung C.S.; Cox F.; Cheung C.Y.; Bakker A.Q.; Bogaards J.A.; van Deventer E.; Preiser W.; Doerr H.W.; Chow VT, de Kruif J, Peiris JS, Goudsmit J., van den Brink EN, ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, de Kruif J, Goudsmit J. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. PLoS Med. 2006. 3(7):e237
• Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, Ter Meulen J, de Kruif J. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J Virol. 2006. 80(14), 6982-6992.
• Goudsmit, J.; Marissen, W.E.; Weldon W.C.; Niezgoda, M.; Hanlon, C.A.; Rice A.B.; Kruif J. de; Dietzschold, B.; Bakker, A.B.; Rupprecht, C.E. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis. 2006. 193(6), 796-801.
• Marissen, W.E.; Kramer, R.A.; Rice, A.; Weldon, W.C.; Niezgoda, M.; Faber, M.; Slootstra, J.W.; Meloen, R.H.; Clijsters-Van Der Horst, M.; Visser, T.J.; Jongeneelen, M.; Thijsse, S.; Throsby, M.; De Kruif, J.; Rupprecht, C.E.; Dietzschold, B.; Goudsmit, J.; Bakker, A.B. Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol. 2005. 79(8), 4672-4678.
• Kramer, R.A.; Marissen, W.E.; Goudsmit, J.; Visser, T.J.; Clijsters-Van Der Horst, M.; Bakker, A.Q.; Jong, M.D.; Jongeneelen, M.; Thijsse, S.; Backus, H.H.; Rice, A.B.; Weldon, W.C.; Rupprecht, C.E.; Dietzschold, B.; Bakker, A.B.; Kruif, J.D. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005. 35(7), 2131-2145.
• Geuijen, C.; Bijl, N.; Smit, R.; Cox, F.; Throsby, M.; Visser, T.; Jongeneelen, M.; Bakker, A.; Kruisbeek, A.; Goudsmit, J.; Kruif, J. A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry. Eur J Cancer. 2005. 41(1), 178-187.
• Daffis, S., Kontermann, R.E., Korimbocus, J., Zeller, H., Klenk, H.D., And Ter Meulen, J. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants. Virology. 2005. 337(2), 262-272.
• Brink, E.; Ter Meulen, J.; Cox, F.; Jongeneelen, M.; Thijsse, A.; Throsby, M.; Marissen, W.; Rood, P.; Bakker, A.; Gelderblom, H.; Martina, B.; Osterhaus, A.; Preiser, W.; Doerr, H.; Kruif, J.; Goudsmit, J. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol. 2005. 79(3), 1635-1644.
• ter Meulen J.; Bakker A.B.; van den Brink E.N.; Weverling G.J.; Martina B.E.; Haagmans B.L.; Kuiken T.; de Kruif J.; Preiser W.; Spaan W.; Gelderblom H.R.; Goudsmit J.; Osterhaus A.D. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. 2004. 363(9427), 2139-2141.
• Kramer R.A.; Cox F.; van der Horst M.; van der Oudenrijn S.; Res P.C.; Bia J.; Logtenberg T.; de Kruif J. A novel helper phage that improves phage display selection efficiency by preventing the amplification of phages without recombinant protein. Nucleic Acids Res. 2003. 1;31(11), e59.
• Radosevic K.; Voerman J.S.; Hemmes A.; Muskens F.; Speleman L.; de Weers M.; Rosmalen J.G.; Knegt P.; van Ewijk W. Colony lift assay using cell-coated filters: a fast and efficient method to screen phage libraries for cell-binding clones. J Immunol Methods. 2003. 272(1-2), 219-233.
• Huls G.; Heijnen I.; Cuomo M.; Koningsberger J.; Wiegman L.; Boel E.; van der Vuurst A.; Loyson S.; Helfrich W.; van Berge Henegouwen G.; van Meijer M.; de Kruif J.; Logtenberg T. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol. 1999. 17(3), 276-281.

• Pfister M.; Kursteiner O.; Hilfiker H.; Favre D.; Durrere P.; Ennaji A.; L'Age-Stehr J.; Kaufhold A.; Herzog C. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg. 2005. 72(3), 339-346.
• Bogaards, J.A.; Ballegooijen, W.M.V.; Jan Weverling, G.; Boerlijst, M.C.; Goudsmit, J. Is population-level perversity a likely outcome of mass vaccination against HIV? Lancet Infect Dis. 2005. 5(5), 254.
• Bakker A.B.; van den Oudenrijn S.; Bakker A.Q.; Feller N.; van Meijer M.; Bia J.A.; Jongeneelen M.A.; Visser T.J.; Bijl N.; Geuijen C.A; Marissen W.E.; Radosevic K.; Throsby M.; Schuurhuis G.J.; Ossenkoppele G.J.; de Kruif J.; Goudsmit J.; Kruisbeek A.M. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004. 64(22), 8443-8450.
• Lemckert A.A.; Goudsmit J.; Barouch D.H. Challenges in the search for an HIV vaccine. Eur J Epidemiol. 2004. 19(6), 513-516.
• Reinhardt B.; Jaspert R.; Niedrig M.; Kostner C.; L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol. 1998. 56(2), 159-167